Repatha (evolocumab) lowers LDL cholesterol by blocking a protein called PCSK9 that your liver naturally produces. This protein normally destroys the receptors on liver cells that pull LDL cholesterol out of your bloodstream. By disabling PCSK9, Repatha allows those receptors to keep working and recycling, so your liver clears far more LDL from your blood. In clinical use, patients typically see LDL reductions of about 56 to 59% from their starting levels.
The PCSK9 Protein and Why It Matters
Your liver cells are covered in LDL receptors, tiny structures that grab LDL particles from the blood and pull them inside the cell for disposal. Each receptor can do this many times over its lifespan. But your body also produces a protein called PCSK9, which binds to those receptors and marks them for destruction. Once a receptor is tagged by PCSK9, it gets broken down instead of returning to the cell surface to grab more LDL.
In people with high cholesterol, especially those with a genetic condition called familial hypercholesterolemia, this process works against them. Their LDL receptors get destroyed too quickly, and cholesterol accumulates in the blood. Statins actually make this worse in one specific way: while they force the liver to produce more LDL receptors (which is how they lower cholesterol), they also increase PCSK9 production. That’s one reason statins alone sometimes aren’t enough.
How Repatha Blocks PCSK9
Repatha is a monoclonal antibody, a lab-engineered protein designed to latch onto PCSK9 before it can reach LDL receptors. Once Repatha binds to PCSK9 in the bloodstream, that PCSK9 molecule is neutralized. It can no longer attach to LDL receptors on liver cells.
The result is straightforward: more LDL receptors survive, return to the cell surface, and keep pulling cholesterol out of the blood. This is why Repatha works well alongside statins. Statins push the liver to make more receptors, and Repatha protects those receptors from being destroyed. The two drugs complement each other through entirely different pathways.
How Much It Lowers Cholesterol
In real-world data from patients with hereditary high cholesterol, Repatha reduced LDL levels by about 56% at six months, with that benefit holding steady at around 59% after two years of treatment. In absolute terms, that translated to an average drop of roughly 111 mg/dL. Patients with the more severe, homozygous form of familial hypercholesterolemia saw reductions of about 44% at six months, improving to around 58% with continued use.
These reductions are on top of whatever other cholesterol-lowering medications the patient is already taking. Most people prescribed Repatha are already on a statin, and many also take ezetimibe, a drug that blocks cholesterol absorption in the gut. Repatha’s mechanism is independent of both, so the effects stack.
Cardiovascular Benefits Beyond Cholesterol Numbers
The landmark FOURIER trial tested whether Repatha’s cholesterol-lowering ability actually translated into fewer heart attacks and strokes. It did. Compared to placebo, patients on Repatha had a 26% lower rate of heart attacks, a 23% lower rate of strokes, and a 22% lower rate of procedures to reopen blocked coronary arteries. All participants in the trial were already on statin therapy, so these benefits came from adding Repatha to standard treatment.
Repatha is FDA-approved both for lowering LDL cholesterol and for reducing the risk of major cardiovascular events in adults, including heart attack, stroke, unstable angina requiring hospitalization, and the need for coronary procedures. It’s also approved for children aged 10 and older with familial hypercholesterolemia.
How You Take It
Repatha is a subcutaneous injection, meaning it goes just under the skin, typically in the thigh, abdomen, or upper arm. You have two dosing options: 140 mg every two weeks or 420 mg once a month. Both schedules produce similar cholesterol-lowering results, so the choice usually comes down to personal preference. The medication comes in prefilled syringes or an autoinjector pen that most people can use at home without help.
After injection, Repatha reaches its peak concentration in the blood within three to four days. Its effective half-life is 11 to 17 days, which is why biweekly or monthly dosing keeps levels consistent. The medication needs to be stored in the refrigerator (2°C to 8°C), but it can sit at room temperature for up to 30 days if kept in its original carton and out of direct sunlight.
Side Effects
Repatha’s side effect profile is relatively mild. In a year-long clinical trial, the most commonly reported issues were ones you’d see in any large group of people: common colds and upper respiratory infections (about 10% of patients), flu (7.5%), back pain (6.2%), and injection site reactions like redness, pain, or bruising (5.7%). These rates were only slightly higher than what patients on placebo reported.
In the large FOURIER cardiovascular outcomes trial, the most frequent side effects occurring more often with Repatha than placebo were diabetes (8.8% vs. 8.2%), cold symptoms (7.8% vs. 7.4%), and upper respiratory infections (5.1% vs. 4.8%). Muscle pain occurred in about 4% of patients in shorter trials, a number worth noting since muscle complaints are a common reason people struggle with statins. Repatha works through a completely different mechanism and does not share statins’ muscle-related issues in any meaningful way.
Cost and Access
Repatha has historically been expensive, which limited its use. As of October 2025, Amgen launched a direct-to-patient program called AmgenNow, offering Repatha at $239 per month, nearly 60% below the previous U.S. list price. What you actually pay depends on your insurance coverage, copay assistance programs, and whether you qualify for the direct program. If cost is a barrier, Amgen and most major insurers have assistance options worth exploring with your pharmacist.